Editorial Team & Standards | Oral Ketamine Tablet Resource
Editorial Team & Standards
Who writes, reviews, and signs off on every article about compounded oral ketamine tablets.
KetamineTablet.com is an independent patient-education resource focused specifically on compounded oral ketamine tablets and rapidly disintegrating tablets (RDTs). Every article is written by health journalists and reviewed by a board-certified psychiatrist, a compounding-pharmacy PharmD, and a licensed integration therapist before publication. We do not sell tablets, do not accept payment from compounding pharmacies, and do not endorse any specific 503A or 503B facility.
About the Author
Dr. Marcus Reyes, MD
Medical Reviewer / Psychiatrist at KetamineTablet.com Editorial Board
Board-certified psychiatrist with subspecialty training in interventional psychiatry. Dr. Reyes reviews every clinical claim on KetamineTablet.com — dosing ranges, contraindications, drug interactions, screening criteria, and off-label prescribing context for oral ketamine.
About the Author
Dr. Hannah Liu, PharmD, FACA
Compounding Pharmacy Reviewer at KetamineTablet.com Editorial Board
Doctor of Pharmacy specializing in 503A non-sterile compounding of oral solid dosage forms — including ketamine tablets and rapidly disintegrating tablets (RDTs). Dr. Liu reviews every article that touches tablet formulation, excipient selection, beyond-use dating, USP <795> compliance, and 503A vs 503B regulatory boundaries.
About the Author
Sarah Whitfield, LCSW, KAP-C
Integration Therapist & Patient Education Lead at KetamineTablet.com Editorial Board
Licensed Clinical Social Worker and certified Ketamine-Assisted Psychotherapy (KAP) practitioner. Sarah reviews patient-facing content on preparation, set-and-setting for at-home oral ketamine sessions, and post-session integration — and is responsible for ensuring our safety-screening language is trauma-informed and clinically appropriate.
Editorial Standards
How we research, review, and update every article.
1. Sources we trust
Articles draw on peer-reviewed literature (PubMed, Cochrane), FDA guidance and warning letters, USP General Chapters (<795>, <797>), statements from the APA, ASKP3, and the Alliance for Pharmacy Compounding (APC), and original primary-source interviews with credentialed clinicians. Marketing materials from compounding pharmacies, telehealth platforms, or manufacturers are explicitly excluded as primary sources.
2. FDA compounding context (503A vs 503B)
Oral ketamine tablets are not FDA-approved products — they are compounded medications prepared under one of two regulatory frameworks:
- 503A pharmacies compound patient-specific prescriptions under state board of pharmacy oversight and USP <795> non-sterile compounding standards. They cannot manufacture in bulk for office stock.
- 503B outsourcing facilities register with the FDA, comply with cGMP, and may produce office-stock quantities — but the specific formulation must still appear on (or be eligible for) the FDA bulks list, and ketamine's status here is narrower.
Every article that references a compounded oral ketamine tablet identifies which regulatory pathway is being described and notes that the product is not FDA-approved for the indication being discussed. We do not direct readers to any specific compounder.
3. Independence and conflicts of interest
KetamineTablet.com does not accept payment, free product, advertising, or affiliate revenue from any compounding pharmacy, 503B outsourcing facility, telehealth ketamine provider, or branded ketamine manufacturer. Reviewers disclose any clinical affiliations on their professional profiles. We do not run sponsored content and we do not publish "best compounder" rankings.
4. Review cadence
Every article carries a "Last Reviewed" date. Clinical, dosing, and regulatory content is re-reviewed at least every 12 months — or sooner when the FDA, DEA, or a relevant professional body issues new guidance affecting compounded ketamine.
5. Corrections
If you find an error, email editorial@ketaminetablet.com. Substantive corrections are noted at the bottom of the corrected article with the original wording, the correction, and the date.
Questions about a specific article or compounder?
We do not recommend or rank individual 503A or 503B compounding pharmacies. For questions about our sourcing, reviewers, or corrections policy, contact our editorial team directly.
Contact Ketamine Tablet
Send corrections, provider questions, or advertising inquiries.